{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:31Z","timestamp":1793908651777,"version":"4.8.0"},"reference-count":429,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["Ta434\/8-1"],"award-info":[{"award-number":["Ta434\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CRC1382 Project-ID 403224013"],"award-info":[{"award-number":["CRC1382 Project-ID 403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5P30DK132710"],"award-info":[{"award-number":["5P30DK132710"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5R01DK128289"],"award-info":[{"award-number":["5R01DK128289"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5R44DK125191"],"award-info":[{"award-number":["5R44DK125191"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","award":["5R01DK128289"],"award-info":[{"award-number":["5R01DK128289"]}],"id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","award":["5P30DK132710"],"award-info":[{"award-number":["5P30DK132710"]}],"id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","award":["5R44DK125191"],"award-info":[{"award-number":["5R44DK125191"]}],"id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jhepr.2025.101421","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:15:03Z","timestamp":1744398903000},"page":"101421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-2098","authenticated-orcid":false,"given":"Robert F.","family":"Schwabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-6195","authenticated-orcid":false,"given":"Scott L.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101421_bib1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib3","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.medj.2024.03.017","article-title":"An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease","volume":"5","author":"Zhang","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","article-title":"Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis","volume":"20","author":"Lee","year":"2024","journal-title":"World J Pediatr"},{"key":"10.1016\/j.jhepr.2025.101421_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib9","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study","volume":"18","author":"Baratta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2024.11.032","article-title":"Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH","volume":"82","author":"Abdurrachim","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","article-title":"Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241276334","article-title":"Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques","volume":"17","author":"Hudson","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101421_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2024.03.035","article-title":"Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases","volume":"81","author":"Thiele","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib25","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6225","article-title":"RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration","volume":"15","author":"Moreno-Lanceta","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib28","article-title":"Understanding the cellular interactome of non-alcoholic fatty liver disease","volume":"4","author":"Wallace","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41586-025-08677-w","article-title":"Hepatic stellate cells control liver zonation, size and functions via R-spondin 3","volume":"640","author":"Sugimoto","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib33","doi-asserted-by":"crossref","DOI":"10.21037\/dmr-21-87","article-title":"Role of the chemokine system in liver fibrosis: a narrative review","volume":"5","author":"Poulsen","year":"2022","journal-title":"Dig Med Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add3949","article-title":"An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/gutjnl-2016-313392","article-title":"The HLF\/IL-6\/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis","volume":"67","author":"Xiang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcmgh.2018.01.003","article-title":"Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis","volume":"5","author":"Zhou","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib38","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-025-01068-6","article-title":"Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease","author":"Schwabe","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib40","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib41","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.24315","article-title":"Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41591-024-03406-8","article-title":"Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial","volume":"31","author":"Brennan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbalip.2008.11.001","article-title":"Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage","volume":"1791","author":"Blaner","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhepr.2025.101421_bib45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1194\/jlr.M029801","article-title":"Hepatic retinoid stores are required for normal liver regeneration","volume":"54","author":"Shmarakov","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib46","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.95811","article-title":"GDF2 and BMP10 coordinate liver cellular crosstalk to maintain liver health","volume":"13","author":"Zhao","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.jhepr.2025.101421_bib47","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmet.2025.01.022","article-title":"Hepatic stellate cells regulate liver fatty acid utilization via plasmalemma vesicle-associated protein","volume":"37","author":"Hansen","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf6696","article-title":"Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation","volume":"16","author":"Trinh","year":"2023","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhepr.2025.101421_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2183\/pjab.82.155","article-title":"Hepatic stellate cells: three-dimensional structure, localization, heterogeneity and development","volume":"82","author":"Wake","year":"2006","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.jhepr.2025.101421_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib51","article-title":"Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib52","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.celrep.2019.10.024","article-title":"Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis","volume":"29","author":"Dobie","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/dvdy.395","article-title":"BMP9 and BMP10: two close vascular quiescence partners that stand out","volume":"251","author":"Desroches-Castan","year":"2022","journal-title":"Dev Dyn"},{"key":"10.1016\/j.jhepr.2025.101421_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/jhep.2001.20793","article-title":"Human and rat hepatic stellate cells express neurotrophins and neurotrophin receptors","volume":"33","author":"Cassiman","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib55","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.82.24.8681","article-title":"Hepatic lipocytes: the principal collagen-producing cells of normal rat liver","volume":"82","author":"Friedman","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib56","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib57","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/hep.31987","article-title":"Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice","volume":"74","author":"Yang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jhepr.2025.101421_bib60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","article-title":"Friend or foe? The elusive role of hepatic stellate cells in liver cancer","volume":"20","author":"Cogliati","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib62","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib63","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2006.08.017","article-title":"Hepatic fibrosis, stellate cells, and portal hypertension","volume":"10","author":"Rockey","year":"2006","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101421_bib64","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2468-1253(23)00111-5","article-title":"Fibroblasts in liver cancer: functions and therapeutic translation","volume":"8","author":"Affo","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib65","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/03008208909103901","article-title":"Collagens of normal and cirrhotic human liver","volume":"23","author":"Aycock","year":"1989","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0016-5085(79)80170-5","article-title":"Collagen types in normal and cirrhotic liver","volume":"76","author":"Rojkind","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/1471-2407-14-518","article-title":"Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver","volume":"14","author":"Naba","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2025.101421_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis - their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2025.101421_bib70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.15184","article-title":"Metabolic dysfunction-associated liver disease and diabetes: matrix remodeling, fibrosis, and therapeutic implications","volume":"1538","author":"Fan","year":"2024","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhepr.2025.101421_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102559","article-title":"Impact of heterogeneity in liver matrix and intrahepatic cells on the progression of hepatic fibrosis","volume":"91","author":"Sun","year":"2024","journal-title":"Tissue Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib72","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib73","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/HEP.0000000000000423","article-title":"Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities","volume":"78","author":"Chen","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28450","article-title":"Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha","volume":"64","author":"Desai","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib75","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI73137","article-title":"Resetting the transcription factor network reverses terminal chronic hepatic failure","volume":"125","author":"Nishikawa","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2023.102208","article-title":"Cellular mechanosignaling for sensing and transducing matrix rigidity","volume":"83","author":"Young","year":"2023","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib77","first-page":"348","article-title":"Mechanical signaling through the discoidin domain receptor 1 plays a central role in tissue fibrosis","volume":"12","author":"Coelho","year":"2018","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.jhepr.2025.101421_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2023.102273","article-title":"Novel roles for cooperating collagen receptor families in fibrotic niches","volume":"85","author":"Zeltz","year":"2023","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib79","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/HEP.0000000000000782","article-title":"Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction","volume":"80","author":"Carter","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib80","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","article-title":"Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis","volume":"135","author":"Taura","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib81","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1038\/s41598-020-60709-9","article-title":"Hypoxia sensing by hepatic stellate cells leads to VEGF-dependent angiogenesis and may contribute to accelerated liver regeneration","volume":"10","author":"Dirscherl","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11901-023-00598-4","article-title":"Emerging therapeutic targets for portal hypertension","volume":"22","author":"Felli","year":"2023","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","article-title":"Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling","volume":"79","author":"Kotsiliti","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.867940","article-title":"Hepatic stellate cell-immune interactions in NASH","volume":"13","author":"Carter","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhepr.2025.101421_bib85","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/bjc.2017.414","article-title":"Inflammatory cytokine IL-8\/CXCL8 promotes tumour escape from hepatocyte-induced dormancy","volume":"118","author":"Khazali","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2025.101421_bib86","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1172\/JCI116753","article-title":"Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines","volume":"92","author":"Marra","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib87","doi-asserted-by":"crossref","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","article-title":"Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration","volume":"285","author":"Schwabe","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2025.101421_bib88","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/hep.28112","article-title":"Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis","volume":"63","author":"Fujita","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib89","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.510240333","article-title":"Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells","volume":"24","author":"Hellerbrand","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib91","first-page":"919","article-title":"Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation","volume":"38","author":"Vinas","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.immuni.2006.11.011","article-title":"Ito cells are liver-resident antigen-presenting cells for activating T cell responses","volume":"26","author":"Winau","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib93","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.4049\/jimmunol.1003917","article-title":"Hepatic stellate cells function as regulatory bystanders","volume":"186","author":"Ichikawa","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/hep.24352","article-title":"Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism","volume":"54","author":"Schildberg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib95","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.4049\/jimmunol.1200819","article-title":"Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO","volume":"189","author":"Sumpter","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/TP.0b013e318294caae","article-title":"Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway","volume":"96","author":"Charles","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2025.101421_bib97","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.21379","article-title":"In vivo immune modulatory activity of hepatic stellate cells in mice","volume":"44","author":"Chen","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib98","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.20488","article-title":"Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice","volume":"40","author":"Yu","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib99","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/TP.0b013e31818bfd13","article-title":"Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner","volume":"86","author":"Jiang","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jhepr.2025.101421_bib100","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1501737","article-title":"Hepatic stellate cells directly inhibit B cells via programmed death-ligand 1","volume":"196","author":"Li","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib101","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.4049\/jimmunol.1201937","article-title":"Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid","volume":"190","author":"Dunham","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib102","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.24162","article-title":"Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice","volume":"53","author":"Chou","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"Yashaswini","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib104","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/jhep.2003.50097","article-title":"Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype","volume":"37","author":"Schnabl","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020652","article-title":"The potential role of cellular senescence in non-alcoholic fatty liver disease","volume":"23","author":"Engelmann","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2025.101421_bib108","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib109","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors","volume":"102","author":"Iredale","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib110","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib111","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib112","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.31743","article-title":"Heterogeneity of HSCs in a mouse model of NASH","volume":"74","author":"Rosenthal","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011858","article-title":"A rule-based multiscale model of hepatic stellate cell plasticity: critical role of the inactivation loop in fibrosis progression","volume":"20","author":"Bougueon","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib114","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/db20-0209","article-title":"The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates","volume":"69","author":"Cui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2025.101421_bib115","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-beta improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101421_bib116","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101421_bib117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib118","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib119","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib120","first-page":"15","article-title":"Once-monthly efimosfermin alfa (Bos580) in metabolic dysfunction- associated steatohepatitis with F2\/F3 fibrosis: results from a 24 week, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.jhepr.2025.101421_bib121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.27279","article-title":"Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis","volume":"61","author":"Hirsova","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib122","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib123","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","author":"Schwabe","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib124","article-title":"Efferocytosis in liver disease","volume":"6","author":"Shi","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib125","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0168-8278(03)00377-5","article-title":"A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo","volume":"39","author":"Kondou","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib126","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib127","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2019.07.036","article-title":"ECM1 prevents activation of transforming growth factor beta, hepatic stellate cells, and fibrogenesis in mice","volume":"157","author":"Fan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/gutjnl-2024-333213","article-title":"ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-beta1 activation","volume":"74","author":"Link","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2024.01.009","article-title":"Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis","volume":"57","author":"Savage","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib130","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib131","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib132","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.devcel.2008.10.015","article-title":"UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators","volume":"15","author":"Rutkowski","year":"2008","journal-title":"Dev Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib133","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1053\/j.gastro.2010.07.046","article-title":"Stress signaling in the methionine-choline-deficient model of murine fatty liver disease","volume":"139","author":"Soon","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib134","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib135","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib136","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cell.2018.08.020","article-title":"ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P","volume":"175","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib137","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.32562","article-title":"Endoplasmic reticulum stress in liver diseases","volume":"77","author":"Ajoolabady","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib138","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.biocel.2010.10.015","article-title":"The role of Hedgehog signaling in fibrogenic liver repair","volume":"43","author":"Choi","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib139","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/hep.25559","article-title":"Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease","volume":"55","author":"Guy","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/path.2888","article-title":"Increased production of sonic hedgehog by ballooned hepatocytes","volume":"224","author":"Rangwala","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.jhepr.2025.101421_bib141","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep.30928","article-title":"Hepatocyte stress increases expression of yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis","volume":"71","author":"Mooring","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib142","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib143","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0344","article-title":"Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis","volume":"10","author":"Zhu","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165369","article-title":"Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis","volume":"8","author":"Kang","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2025.101421_bib146","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adc9653","article-title":"Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis","volume":"15","author":"Xiao","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155975","article-title":"Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"158","author":"Afonso","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jhepr.2025.101421_bib148","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10620-014-3167-6","article-title":"Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model","volume":"59","author":"Thapaliya","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2025.101421_bib149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.redox.2016.05.003","article-title":"Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration","volume":"9","author":"Carlson","year":"2016","journal-title":"Redox Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib150","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41467-022-28718-6","article-title":"Targeting ferroptosis protects against experimental (multi)organ dysfunction and death","volume":"13","author":"Van Coillie","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib151","article-title":"Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101421_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105088","article-title":"Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation","volume":"102","author":"Peleman","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2025.101421_bib153","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41418-024-01348-9","article-title":"Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Peleman","year":"2024","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jhepr.2025.101421_bib154","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhepr.2025.101421_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201369","article-title":"Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase","volume":"13","author":"Hinman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2025.101421_bib156","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib157","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib158","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/hep.30093","article-title":"High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice","volume":"68","author":"Ge","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe5795","article-title":"The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver","volume":"14","author":"Mederacke","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib161","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib162","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.immuni.2022.08.002","article-title":"Liver macrophages in health and disease","volume":"55","author":"Guilliams","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib163","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib164","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jhep.2011.10.026","article-title":"Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution","volume":"56","author":"Ramachandran","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-3-031-65944-7_7","article-title":"Liver macrophage diversity in health and disease","volume":"74","author":"Horn","year":"2024","journal-title":"Results Probl Cell Differ"},{"key":"10.1016\/j.jhepr.2025.101421_bib166","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HEP.0000000000000270","article-title":"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression","volume":"78","author":"Guillot","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib167","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41575-024-00915-2","article-title":"Spatial genomics: mapping human steatotic liver disease","volume":"21","author":"Matchett","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib168","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000491","article-title":"Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context","volume":"8","author":"Guillot","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib169","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001160","article-title":"Reprogramming macrophages to treat liver diseases","author":"Simon-Codina","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib170","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A subset of Kupffer cells regulates metabolism through the expression of CD36","volume":"54","author":"Bleriot","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib171","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib172","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib173","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib174","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"Hendrikx","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"Ganguly","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib176","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.immuni.2025.01.002","article-title":"Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair","volume":"58","author":"De Ponti","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib177","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.immuni.2024.08.016","article-title":"Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Guo","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2025.101421_bib178","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq5202","article-title":"Kupffer cell-like syncytia replenish resident macrophage function in the fibrotic liver","volume":"381","author":"Peiseler","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101421_bib179","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib181","doi-asserted-by":"crossref","first-page":"G200","DOI":"10.1152\/ajpgi.2001.281.1.G200","article-title":"Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine","volume":"281","author":"Rivera","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2025.101421_bib182","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib183","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib184","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","article-title":"Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis","volume":"31","author":"Cai","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib185","doi-asserted-by":"crossref","first-page":"eadp4726","DOI":"10.1126\/sciadv.adp4726","article-title":"Acute contact with profibrotic macrophages mechanically activates fibroblasts via alphavbeta3 integrin-mediated engagement of Piezo1","volume":"10","author":"Ezzo","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhepr.2025.101421_bib186","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hep.26429","article-title":"Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice","volume":"58","author":"Pradere","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib187","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib188","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","article-title":"Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis","volume":"178","author":"Fallowfield","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib189","first-page":"81","article-title":"The elusive antifibrotic macrophage","volume":"2","author":"Adhyatmika","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2025.101421_bib190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166954","article-title":"Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models","volume":"133","author":"Feng","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib191","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib192","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1055\/s-0039-1688502","article-title":"Macrophages as a cell-based therapy for liver disease","volume":"39","author":"Starkey Lewis","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101421_bib193","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib194","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib195","series-title":"Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH]. The Liver Meeting\u00ae","author":"Newsome","year":"2024"},{"key":"10.1016\/j.jhepr.2025.101421_bib196","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib197","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib198","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","article-title":"Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program","volume":"167","author":"Premkumar","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib199","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12072-024-10667-5","article-title":"The contribution of genetics and epigenetics to MAFLD susceptibility","volume":"18","author":"Moretti","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2025.101421_bib200","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib201","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib202","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib203","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib204","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41575-024-00955-8","article-title":"A roadmap for clinical trials in MASH-related compensated cirrhosis","volume":"21","author":"Pericas","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102377","article-title":"Resmetirom's approval: highlighting the need for comprehensive approaches in NASH therapeutics","volume":"48","author":"Alshehade","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101421_bib207","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib208","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib209","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O'Farrell","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib211","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101421_bib213","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/joim.13751","article-title":"Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework","volume":"295","author":"Yang","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib214","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib215","author":"Adams"},{"key":"10.1016\/j.jhepr.2025.101421_bib216","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib217","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib218","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhepr.2025.101421_bib219","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib221","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075361","article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease","volume":"8","author":"Traber","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.jhepr.2025.101421_bib222","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib223","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jcmgh.2023.03.002","article-title":"The multifaceted roles of macrophages in NAFLD pathogenesis","volume":"15","author":"Vonderlin","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib224","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib225","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jhep.2020.02.031","article-title":"Alternatively activated macrophages promote resolution of necrosis following acute liver injury","volume":"73","author":"Starkey Lewis","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib226","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib227","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib228","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib229","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib230","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib231","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib232","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib233","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib234","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib235","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib236","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib237","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jchf.2024.09.004","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jhepr.2025.101421_bib238","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhepr.2025.101421_bib239","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib240","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2025.101421_bib241","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib242","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib243","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","author":"Borlaug","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib244","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib246","article-title":"Tirzepatide for obesity treatment and diabetes prevention","author":"Jastreboff","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib247","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-Receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib248","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib249","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib250","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jhep.2021.12.019","article-title":"Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis","volume":"76","author":"Garrido","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib251","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150632","article-title":"FoxD1 expression identifies a distinct subset of hepatic stellate cells involved in liver fibrosis","volume":"734","author":"Yamagata","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib253","article-title":"Hepatic stellate cells in zone 1 engage in capillarization rather than myofibroblast formation in murine liver fibrosis","volume":"14","author":"Khan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib254","first-page":"101223","article-title":"Hepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease aetiologies","volume":"7","author":"Merens","year":"2024","journal-title":"J Hep Reports"},{"key":"10.1016\/j.jhepr.2025.101421_bib255","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-beta signaling in health and disease","volume":"186","author":"Massague","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib256","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jhepr.2025.101421_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/ph17040533","article-title":"Advances and challenges in targeting TGF-beta isoforms for therapeutic intervention of cancer: a mechanism-based perspective","volume":"17","author":"Danielpour","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhepr.2025.101421_bib258","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1242\/dev.121.6.1845","article-title":"Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice","volume":"121","author":"Dickson","year":"1995","journal-title":"Development"},{"key":"10.1016\/j.jhepr.2025.101421_bib259","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib260","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aau2909","article-title":"Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells","volume":"362","author":"Lienart","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101421_bib261","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-022-32655-9","article-title":"Specificity of TGF-beta1 signal designated by LRRC33 and integrin alpha(V)beta(8)","volume":"13","author":"Duan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib262","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2003.09.053","article-title":"Solution structure of the third TB domain from LTBP1 provides insight into assembly of the large latent complex that sequesters latent TGF-beta","volume":"334","author":"Lack","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib263","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adn6052","article-title":"An antibody that inhibits TGF-beta1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis","volume":"17","author":"Jackson","year":"2024","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhepr.2025.101421_bib264","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe0407","article-title":"TGFbeta2 and TGFbeta3 isoforms drive fibrotic disease pathogenesis","volume":"13","author":"Sun","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib265","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.medj.2023.12.011","article-title":"Isoform-selective TGF-beta3 inhibition for systemic sclerosis","volume":"5","author":"Sun","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103224","article-title":"Engineering T-cell receptor-like antibodies for biologics and cell therapy","volume":"90","author":"Hoydahl","year":"2024","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jhepr.2025.101421_bib267","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib268","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jhepr.2025.101421_bib269","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models","volume":"80","author":"Dai","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158207","article-title":"Senescent hepatic stellate cells promote liver regeneration through IL-6 and ligands of CXCR2","volume":"7","author":"Cheng","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2025.101421_bib271","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","article-title":"Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis","volume":"77","author":"Du","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib272","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl7209","article-title":"Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma","volume":"7","author":"Yamagishi","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib273","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.4077","article-title":"Extracellular vesicles originating from steatotic hepatocytes promote hepatic stellate cell senescence via AKT\/mTOR signaling","volume":"42","author":"Wu","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.jhepr.2025.101421_bib274","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2021.111572","article-title":"Hepatic stellate cell senescence in liver fibrosis: characteristics, mechanisms and perspectives","volume":"199","author":"Zhang","year":"2021","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.jhepr.2025.101421_bib275","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13767","article-title":"Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age","volume":"22","author":"Islam","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.jhepr.2025.101421_bib276","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1761-7","article-title":"Author Correction: targeting cardiac fibrosis with engineered T cells","volume":"576","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib277","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","article-title":"Targeting immune-fibroblast cell communication in heart failure","volume":"635","author":"Amrute","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib278","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12951-024-02946-y","article-title":"Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration","volume":"22","author":"Zhao","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.jhepr.2025.101421_bib279","doi-asserted-by":"crossref","DOI":"10.3390\/biom13121718","article-title":"Fibroblast activation protein alpha (FAPalpha) in fibrosis: beyond a perspective marker for activated stromal cells?","volume":"13","author":"Basalova","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jhepr.2025.101421_bib280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101421_bib281","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMcibr2201182","article-title":"Fighting cardiac fibrosis with CAR T cells","volume":"386","author":"Friedman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib282","article-title":"In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis","author":"Yashaswini","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhepr.2025.101421_bib283","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111540","article-title":"Radiotracers for imaging of fibrosis: advances during the last two decades and future directions","volume":"16","author":"Eriksson","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhepr.2025.101421_bib284","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s12265-022-10351-9","article-title":"The pathobiology of interleukin 11 in mammalian disease is likely explained by its essential evolutionary role for fin regeneration","volume":"16","author":"Cook","year":"2023","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib285","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1042\/BCJ20220160","article-title":"Understanding interleukin 11 as a disease gene and therapeutic target","volume":"480","author":"Cook","year":"2023","journal-title":"Biochem J"},{"key":"10.1016\/j.jhepr.2025.101421_bib286","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1038\/s41467-022-35306-1","article-title":"Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease","volume":"13","author":"Widjaja","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib287","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168900","article-title":"IL11 stimulates IL33 expression and proinflammatory fibroblast activation across tissues","volume":"23","author":"Widjaja","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2025.101421_bib288","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","article-title":"Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis","volume":"157","author":"Widjaja","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib289","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-024-01436-2","article-title":"Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 phase 1 studies","volume":"47","author":"Mor","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhepr.2025.101421_bib290","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/acr.25344","article-title":"Serum CCL24 as a biomarker of fibrotic and vascular disease severity in systemic sclerosis","volume":"76","author":"De Lorenzis","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jhepr.2025.101421_bib291","article-title":"A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage","volume":"2","author":"Segal-Salto","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib292","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice","volume":"54","author":"Bansal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib293","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-0716-3207-9_17","article-title":"Hepatic stellate cell targeting using peptide-modified biologicals","volume":"2669","author":"Bansal","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib294","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2025.101421_bib295","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects","volume":"57","author":"Klein","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib296","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-022-29186-8","article-title":"Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib297","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.23419","article-title":"Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats","volume":"51","author":"Moreno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib298","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1021\/acs.molpharmaceut.6b01174","article-title":"Highly selective targeting of hepatic stellate cells for liver fibrosis treatment using a d-enantiomeric peptide ligand of Fn14 identified by mirror-image mRNA display","volume":"14","author":"Huang","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jhepr.2025.101421_bib299","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jconrel.2020.09.041","article-title":"Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs) ameliorate hepatic stellate cells activation in vitro and acute liver injury in vivo","volume":"328","author":"Kurniawan","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.jhepr.2025.101421_bib300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2018.01.020","article-title":"Integrins in wound healing, fibrosis and tumor stroma: high potential targets for therapeutics and drug delivery","volume":"129","author":"Schnittert","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2025.101421_bib301","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2025.101421_bib302","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib303","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.1201851","article-title":"Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication","volume":"189","author":"Dragomir","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2025.101421_bib304","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2025.101421_bib305","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib306","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Al Attar","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101421_bib307","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj4221","article-title":"A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity","volume":"14","author":"Roehlen","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib308","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib309","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s43018-023-00614-y","article-title":"A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer","volume":"4","author":"Chitty","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhepr.2025.101421_bib310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf0133","article-title":"LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung","volume":"9","author":"Ma","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhepr.2025.101421_bib311","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/HEP.0000000000000980","article-title":"Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: results of multimodality assessment using both conventional and digital pathology","volume":"81","author":"Ratziu","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib312","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib313","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib314","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"Hernandez-Gea","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib315","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/13543784.2022.2159804","article-title":"Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH","volume":"31","author":"Fraser","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhepr.2025.101421_bib316","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1111\/liv.14643","article-title":"Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative","volume":"40","author":"Stokman","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101421_bib317","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1453","article-title":"Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice","volume":"4","author":"van den Hoek","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib318","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib319","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jhep.2024.01.032","article-title":"Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models","volume":"80","author":"Caon","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib320","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrm3598","article-title":"The mechanisms of Hedgehog signalling and its roles in development and disease","volume":"14","author":"Briscoe","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib321","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/a-2187-3382","article-title":"Hedgehog signaling: implications in liver pathophysiology","volume":"43","author":"Dutta","year":"2023","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101421_bib322","first-page":"14574","article-title":"Suppression of hedgehog signaling regulates hepatic stellate cell activation and collagen secretion","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jhepr.2025.101421_bib323","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2017.12.022","article-title":"Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells","volume":"154","author":"Du","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib324","first-page":"2380","article-title":"Smoothened is a master regulator of adult liver repair","volume":"123","author":"Michelotti","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib325","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/10409238.2018.1448752","article-title":"The hedgehog pathway in nonalcoholic fatty liver disease","volume":"53","author":"Verdelho Machado","year":"2018","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib326","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180310","article-title":"The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression","volume":"134","author":"Jun","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib327","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.26511","article-title":"Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice","volume":"58","author":"Xie","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib328","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104064","article-title":"Unveiling the role of the Hedgehog signaling pathway in chronic liver disease: therapeutic insights and strategies","volume":"29","author":"Nair","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jhepr.2025.101421_bib329","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","article-title":"Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis","volume":"125","author":"Weston","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib330","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.27942","article-title":"Vascular adhesion protein 1 in nonalcoholic steatohepatitis: a novel biomarker?","volume":"62","author":"Torok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib331","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib332","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib333","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123294","article-title":"ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model","volume":"5","author":"Schuster-Gaul","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2025.101421_bib334","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4062\/biomolther.2020.016","article-title":"Selonsertib inhibits liver fibrosis via downregulation of ASK1\/MAPK pathway of hepatic stellate cells","volume":"28","author":"Yoon","year":"2020","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.jhepr.2025.101421_bib335","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.1840380414","article-title":"p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts","volume":"38","author":"Furukawa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib336","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2009.09.015","article-title":"Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition","volume":"138","author":"Kluwe","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib337","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2018.02.045","article-title":"Thyroid hormones and cardiovascular function and diseases","volume":"71","author":"Razvi","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhepr.2025.101421_bib338","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/dom.16117","article-title":"Hepatic thyroid hormone receptor-beta signalling: mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis","volume":"27","author":"Polyzos","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib339","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.jhepr.2025.101421_bib340","author":"Viking"},{"key":"10.1016\/j.jhepr.2025.101421_bib341","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101421_bib342","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jhepr.2025.101421_bib343","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40139-015-0094-y","article-title":"Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver","volume":"3","author":"Park","year":"2015","journal-title":"Curr Pathobiol Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib344","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2015.11.012","article-title":"Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta\/smad2\/3 and NF-kappaB signaling pathways","volume":"290","author":"Xu","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101421_bib346","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/dna.2013.2290","article-title":"FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1\/2-PPARgamma-LXRalpha pathway in THP1 macrophage-derived foam cells","volume":"33","author":"Lin","year":"2014","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101421_bib347","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BJ20151085","article-title":"Circulating FGF21 proteolytic processing mediated by fibroblast activation protein","volume":"473","author":"Zhen","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.jhepr.2025.101421_bib348","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib349","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib350","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161282","article-title":"Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models","volume":"8","author":"Matsukawa","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2025.101421_bib351","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib352","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib353","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib354","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1038\/s41598-020-63579-3","article-title":"Hepatocyte-specific deletion of Pparalpha promotes NAFLD in the context of obesity","volume":"10","author":"Regnier","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib355","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nature12710","article-title":"A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use","volume":"502","author":"Liu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib356","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0155","article-title":"Role of hepatic peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver disease","volume":"257","author":"Lee","year":"2023","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jhepr.2025.101421_bib357","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2020.01.027","article-title":"Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib358","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib359","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib360","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib361","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib362","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib363","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhepr.2025.101421_bib364","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib366","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study","volume":"79","author":"Engstrom","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib367","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib368","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101421_bib369","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"Wester","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101421_bib370","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and efficacy of novel incretin Co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib371","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73815-5","article-title":"Receptor occupancy of dual glucagon-like peptide 1\/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes","volume":"10","author":"Eriksson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101421_bib372","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib373","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib374","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064721","article-title":"Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH","volume":"8","author":"Bjursell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2025.101421_bib376","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhepr.2025.101421_bib377","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2013.12.003","article-title":"Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice","volume":"60","author":"Xiong","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib378","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhepr.2025.101421_bib379","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101421_bib380","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101421_bib381","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib382","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib383","author":"Northsea"},{"key":"10.1016\/j.jhepr.2025.101421_bib384","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib385","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jhepr.2025.101421_bib386","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib387","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jhepr.2025.101421_bib388","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: a randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2025.101421_bib389","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jhepr.2025.101421_bib390","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhepr.2025.101421_bib391","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","article-title":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","volume":"754","author":"Hayashizaki-Someya","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhepr.2025.101421_bib392","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00535-016-1200-6","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats","volume":"51","author":"Nishimura","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101421_bib393","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jhepr.2025.101421_bib394","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib395","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib396","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.30822","article-title":"Hepatocyte TNF receptor-associated factor 6 aggravates hepatic inflammation and fibrosis by promoting lysine 6-linked polyubiquitination of apoptosis signal-regulating kinase 1","volume":"71","author":"Wang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib397","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib398","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/14728222.9.2.267","article-title":"Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition","volume":"9","author":"Harwood","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jhepr.2025.101421_bib399","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101421_bib400","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib401","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib402","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib403","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/d41586-018-05867-7","article-title":"Gene-silencing technology gets first drug approval after 20-year wait","volume":"560","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2025.101421_bib404","first-page":"e69","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib405","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102184","article-title":"Oligonucleotide therapies for nonalcoholic steatohepatitis","volume":"35","author":"Li","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhepr.2025.101421_bib406","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2017.74","article-title":"NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD","volume":"14","author":"Mann","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib407","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2025.101421_bib408","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Linden","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhepr.2025.101421_bib409","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20121689","article-title":"Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia","volume":"451","author":"Zammit","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.jhepr.2025.101421_bib411","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhepr.2025.101421_bib412","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib413","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib414","first-page":"S1","article-title":"Novel DGAT antisense inhibitor demonstrates significant histological benefit in biopsy-proven mash patients with advanced liver fibrosis stage F3: subset analysis of a 51-week multicenter randomized double-blind placebo-controlled phase 2 trial","volume":"80","author":"Loomba","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib415","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2018.10.014","article-title":"Role of HSD17B13 in the liver physiology and pathophysiology","volume":"489","author":"Su","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jhepr.2025.101421_bib416","article-title":"HSD17B13: a potential therapeutic target for NAFLD","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jhepr.2025.101421_bib417","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib418","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2025.101421_bib419","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101421_bib420","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-beta dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhepr.2025.101421_bib421","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib422","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1096\/fj.201900356RR","article-title":"Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans","volume":"33","author":"Cansby","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.jhepr.2025.101421_bib423","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002671RR","article-title":"Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease","volume":"35","author":"Caputo","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.jhepr.2025.101421_bib424","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/hep4.1405","article-title":"A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101421_bib425","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib426","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib427","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101421_bib428","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib429","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101421_bib430","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T08:09:58Z","timestamp":1755245398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":429,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589555925000989"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101421","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101421"}}